Patient with neuromyelitis optica spectrum disorder combined with Sjögren's syndrome relapse free following tacrolimus treatment

Internal Medicine

Volumn 53, Issue 20, 2014, Pages 2377-2380

  Zheng, Xueping ^a   Zhang, Xu ^a   Liu, Xuejun ^a   Mu, Wenfeng ^b   Yang, Wenru ^a   Liu, Youxin ^a   Ge, Ping ^a   Li, Haifeng ^a  

^a QINGDAO UNIVERSITY   (China)

^b QINGDAO WOMEN AND CHILDREN S HOSPITAL   (China)

Author keywords

Cyclophosphamide; Neuromyelitis optica; Neuromyelitis optica spectrum disorder; Sj gren's syndrome; Tacrolimus

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; LA ANTIBODY; PREDNISOLONE; RO ANTIBODY; TACROLIMUS; AUTOANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DISABILITY; DRUG MEGADOSE; DRUG SUBSTITUTION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEMUR HEAD NECROSIS; HIP DISEASE; HUMAN; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PTOSIS; QUADRIPLEGIA; RELAPSE; SCHIRMER TEST; SJOEGREN SYNDROME; URINE RETENTION; IMMUNOLOGY; NEUROMYELITIS OPTICA; SJOGREN'S SYNDROME; TUMOR RECURRENCE;

ADULT; AUTOANTIBODIES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; NEOPLASM RECURRENCE, LOCAL; NEUROMYELITIS OPTICA; SJOGREN'S SYNDROME; TACROLIMUS;

EID: 84907969813     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.0814     Document Type: Article

References (16)

1. Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Opin Neurol 20: 255-260, 2007.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 6: 805-815, 2007.
3. Kolfenbach JR, Horner BJ, Ferucci ED, West SG. Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care Res (Hoboken) 63: 1203-1208, 2011.
4. Kahlenberg JM. Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjögren's syndrome. Semin Arthritis Rheum 40: 343-348, 2011.
5. Thomson AW, Carroll PB, McCauley J, et al. FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. Springer Semin Immunopathol 14: 323-344, 1993.
6. Ponseti JM, Gamez J, Azem J, López-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci 1132: 254-263, 2008.
7. Ishigaki K, Shishikura K, Murakami T, Suzuki H, Hirayama Y, Osawa M. Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis. Brain Dev 31: 634- 637, 2009.
8. Inamura N, Hashimoto M, Nakahara K, et al. Immunosuppressive effect of FK506 on experimental allergic encephalomyelitis in rats. Int J Immunopharmacol 10: 991-995, 1988.
9. Kageyama T, Komori M, Miyamoto K, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 260: 627-634, 2013.
10. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14: 1157-1174, 2008.
11. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-558, 2002.
12. Kolfenbach JR, Horner BJ, Ferucci ED, West SG. Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care Res (Hoboken) 63: 1203-1208, 2011.
13. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65: 78-83, 2008.
14. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131: 3072- 3080, 2008.
15. Ozgocmen S, Gur A. Treatment of central nervous system involvement associated with primary Sjögren's syndrome. Curr Pharm Des 14: 1270-1273, 2008.
16. Yaguchi H, Sakushima K, Takahashi I, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med 52: 969-972, 2013.